Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SRZN Stock Summary
In the News
Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher
Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
5 Top Stocks Likely to Come Up With Earnings Beat
These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).
New Strong Buy Stocks for April 12th
CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.
Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023
SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress.
How to Diversify Your Penny Stock Investments
Use these tips for diversifying your investments in penny stocks The post How to Diversify Your Penny Stock Investments appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now
High volume penny stocks to watch right now. The post Penny Stocks To Buy?
Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present on January 12, 2023 at 7:30 a.m. Pacific time at the 41st Annual J.P. Morgan Healthcare Conference.
Surrozen, Inc. (SRZN) Upgraded to Buy: Here's What You Should Know
Surrozen, Inc. (SRZN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
Surrozen to provide a business update including discussion of pipeline advancements Surrozen to provide a business update including discussion of pipeline advancements
Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22. Interested parties may access the live webcast via the Investors section of the Surrozen website at www.surrozen.com. A replay of the webcast will be archived on the website.
SRZN Financial details
SRZN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
|Revenue per share||0||0||0.36|
|Net income per share||-0.93||-2.13||-0.8|
|Operating cash flow per share||-0.83||-1.98||-1.27|
|Free cash flow per share||-0.86||-2.03||-1.29|
|Cash per share||1.4||4.13||2.18|
|Book value per share||1.35||4.44||2.19|
|Tangible book value per share||1.35||4.44||2.19|
|Share holders equity per share||1.35||4.44||2.19|
|Interest debt per share||0.27||0.32||0.11|
|Price to sales ratio||0||0||1.62|
|EV to sales||0||0||0.09|
|Enterprise value over EBITDA||-10.65||-2.46||-0.03|
|EV to operating cash flow||-11.3||-2.74||-0.03|
|EV to free cash flow||-10.97||-2.67||-0.02|
|Free cash flow yield||-0.08||-0.31||-2.22|
|Debt to equity||0.2||0.07||0.07|
|Debt to assets||0.15||0.06||0.06|
|Net debt to EBITDA||0.82||0.47||0.43|
|Sales general and administrative to revenue||0||0||1.59|
|Research and developement to revenue||0||0||2.96|
|Intangibles to total assets||0||0||0|
|Capex to operating cash flow||0.03||0.03||0.02|
|Capex to revenue||0||0||-0.06|
|Capex to depreciation||-0.45||-0.61||-0.37|
|Stock based compensation to revenue||0||0||0.36|
|Return on tangible assets||-0.53||-0.38||-0.31|
|Tangible asset value||47.29M||109.7M||76M|
|Net current asset value||35.46M||77.72M||67.87M|
|Days sales outstanding||0||0||57.76|
|Days payables outstanding||0||0||0|
|Days of inventory on hand||0||0||0|
|Capex per share||-0.02||-0.05||-0.02|
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
|Revenue per share||0||0.36||0||0||0|
|Net income per share||-0.37||0.21||-0.53||-0.31||-0.34|
|Operating cash flow per share||-0.4||-0.01||-0.47||-0.29||-0.33|
|Free cash flow per share||-0.41||-0.01||-0.48||-0.29||-0.33|
|Cash per share||2.24||2.18||2.06||1.78||1.42|
|Book value per share||2.22||2.19||2.1||1.83||1.49|
|Tangible book value per share||2.22||2.19||2.1||1.83||1.49|
|Share holders equity per share||2.22||2.19||2.1||1.83||1.49|
|Interest debt per share||0.16||0.34||0.16||0.15||0.13|
|Price to sales ratio||0||1.62||0||0||0|
|EV to sales||0||0.09||0||0||0|
|Enterprise value over EBITDA||-3.76||-0.51||0.39||1.58||1.96|
|EV to operating cash flow||-3.62||-5.45||0.33||1.76||1.49|
|EV to free cash flow||-3.58||-3.16||0.32||1.75||1.49|
|Free cash flow yield||-0.2||-0.02||-0.8||-0.53||-0.68|
|Debt to equity||0.08||0.07||0.08||0.08||0.09|
|Debt to assets||0.07||0.06||0.07||0.07||0.07|
|Net debt to EBITDA||1.43||8.8||1.87||3.27||3.9|
|Sales general and administrative to revenue||0||0.42||0||0||0|
|Research and developement to revenue||0||0.75||0||0||0|
|Intangibles to total assets||0||0||0||0||0|
|Capex to operating cash flow||0.01||0.72||0.02||0.01||0|
|Capex to revenue||0||-0.01||0||0||0|
|Capex to depreciation||-0.31||-0.31||-0.65||-0.17||0|
|Stock based compensation to revenue||0||0.12||0||0||0|
|Return on tangible assets||-0.14||0.08||-0.21||-0.15||-0.19|
|Tangible asset value||77.49M||76M||63.04M||55.06M||45.53M|
|Net current asset value||68.78M||67.87M||55.87M||48.64M||39.92M|
|Days sales outstanding||0||14.24||0||0||0|
|Days payables outstanding||0||0||0||0||0|
|Days of inventory on hand||0||0||0||0||0|
|Capex per share||0||0||-0.01||0||0|
SRZN Frequently Asked Questions
What is Surrozen, Inc. stock symbol ?
Surrozen, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol SRZN
What is Surrozen, Inc. stock quote today ?
Surrozen, Inc. stock price is $0.4497 today.
Is Surrozen, Inc. stock public?
Yes, Surrozen, Inc. is a publicly traded company.